The Biologics Development Roadmap

Biological products are not regulated like small-molecule drugs, and they are not developed like them either. Monoclonal antibodies, viral-vector gene therapies, engineered cell therapies, and vaccines share almost nothing at the bench, but they go through the same FDA process: they are studied in humans under an Investigational New Drug application (IND) and brought to market under a Biologics License Application (BLA), reviewed either by the Center for Drug Evaluation and Research (CDER) or the Center for Biologics Evaluation and Research (CBER).

For cell and gene therapies, all interactions start with CBER’s Office of Therapeutic Products (OTP), the expanded office that replaces the former Office of Tissues and Advanced Therapies. These products are often first-in-class, built on novel platforms, and manufactured in ways that have no direct precedent. That novelty is exactly why FDA built a stage-gated series of formal meetings intertwined with the development process.

This explainer lays out the terrain: what a biologic is, the two applications that bracket clinical development, the phase-by-phase roadmap to a BLA, how CBER actually reviews these products, and where each FDA meeting - INTERACT, pre-IND, end-of-phase, pre-BLA - earns its place in the plan.

01 · THE PRODUCT

What counts as a biologic

A biological product is, broadly, a product derived from living systems used to prevent, treat, or cure a condition in humans. A very diverse set of products are included in this description including viruses, therapeutic serums, toxins, antitoxins, vaccines, blood and blood components, allergenics, and therapeutic proteins.

Most biologics are licensed under Section 351 of the Public Health Service (PHS) Act and reviewed by CBER. This is the world of “351 products,” as distinct from low-risk human tissue products regulated solely under Section 361 of the PHS Act and 21 CFR Part 1271, which need no premarket application at all.

Within CBER, review responsibility is organized by product area. Cell therapies, gene therapies, and other regenerative medicine products fall to OTP. Vaccines, blood products, and allergenics sit with other CBER offices. Knowing your review office matters because it shapes which SOPs, Guidances apply, which reviewers you talk to, and which expedited programs are open to you.

ONE FRAMEWORK, VERY DIFFERENT PRODUCTS

A CAR-T cell product, an AAV gene therapy, and an influenza vaccine are all biologics licensed under PHS Act §351. They follow the same IND to BLA arc but raise sharply different questions on manufacturing, potency, dosing, and long-term follow-up. The roadmap is shared; the evidence package is bespoke.

02 · THE FRAMEWORK

Two applications bracket the journey

Two regulatory submissions define the clinical life of a biologic. The IND is what lets you put an investigational product into people; the BLA is what lets you market it. Everything in between is the work of generating the evidence to get from one to the other.

IND · to study in humans

BLA · to market

Regulation

21 CFR Part 312

21 CFR Part 601

Purpose

Authorizes administration of an investigational biologic to humans

Authorizes marketing of a biologic in interstate commerce

Core content

Preliminary CMC, pharmacology/toxicology, clinical protocol, Investigator’s Brochure

Full commercial CMC package, nonclinical and clinical data, labeling, facility and manufacturing information

FDA clock

Study may begin 30 days after receipt unless placed on clinical hold

Goal-date review under PDUFA; filing review then substantive review; FDA’s final decision also relies on an inspection, which needs to be scheduled during the BLA

An IND is not “approved” in the way a BLA is. It becomes effective by default: if FDA does not place the application on clinical hold within 30 days, the proposed study may proceed. A 30 day review clock is extremely short for FDA, and there is limited opportunity for the review team to address issues. That 30-day window is one reason the quality of your IND-enabling work, and the advice you gather before filing, matters so much.

03 · THE ROADMAP

From discovery to a licensed product

Development moves through recognizable stages. The timeline below is a simplification but shows the shape of the journey and the natural points where FDA input is most valuable. For your specific program, you can expect program iterations, phases that overlap, and manufacturing changes throughout.

Stage

What happens

Typical FDA touchpoint

Discovery & preclinical

Candidate selection, proof-of-concept, early manufacturing, IND-enabling toxicology

INTERACT, then pre-IND

IND filing

Assemble CMC, pharm/tox, and first-in-human protocol; 30-day review

IND submission

Phase 1

First-in-human: safety, dose, biologic activity

Type C / Type D as needed

Phase 2

Dose-finding and preliminary efficacy in the target population

End-of-Phase 2 (Type B)

Phase 3

Confirmatory efficacy and safety

Type C / Type D as needed

Pre-BLA

Preparation prior to the BLA, intended to address anticipated issues

Pre-BLA (Type B),

BLA

Marketing application; filing, review, possible advisory committee, inspection, action

BLA

Post-market

Pharmacovigilance, post-marketing requirements, long-term follow-up

Post-marketing meetings

Cell and gene therapies add a wrinkle the table cannot capture: manufacturing and the product are deeply intertwined. A change in vector production or cell expansion can change the product itself, so CMC and comparability questions recur at every stage rather than settling early. This is part of why OTP encourages frequent, early engagement.

04 · THE REVIEW

How CBER evaluates a biologic

CBER review is multidisciplinary. A submission is read in parallel by reviewers across product quality (CMC), pharmacology/toxicology, clinical, clinical pharmacology, statistics, facility and product quality inspection. Each discipline asks its own questions, and a program can be slowed by a weakness in any one of them.

For a BLA, review runs on PDUFA goal dates. FDA first decides whether the application is complete enough to file, then conducts a substantive review that may include an advisory committee meeting and a pre-license inspection of manufacturing facilities. The review ends in an action: approval, or a complete response letter (CR letter) identifying what stands in the way.

Because so much is decided by the quality of the evidence package, the most effective applicants treat FDA not as a gate at the end but as a counterparty throughout. Smart applicants use meetings to resolve disagreements on study design, endpoints, and manufacturing while there is still time to act on them.

05 · THE MEETING LADDER

Where FDA interactions fit

FDA offers a structured set of formal meetings for drugs and biologics, each matched to a stage of development. They are defined in the guidance Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products and, for CBER, in SOPP 8101.1. The earliest rung is INTERACT; the rest follow as the program matures.

Meeting

When it fits

Focus

INTERACT

Before pre-IND / before the IND

Novel, early IND-enabling challenges

Pre-IND (Type B)

As you prepare to file the IND

IND-enabling tox, CMC, first-in-human design

Type B (EOP)

End of Phase 1 or Phase 2

Readiness to advance to the next phase

Type C

Any other development question

Targeted scientific or regulatory issues

Type D

A narrow, focused issue

One or two topics, few disciplines

Pre-BLA (Type B)

Months before submitting the BLA

Format and content of the application

MEETINGS ARE MILESTONES, NOT FORMALITIES

Each meeting type has its own request timeline, package requirements, and goal dates. Used well, they convert FDA’s thinking into something you can plan around. Trying to raise issues via the wrong meeting type, with premature timing, or a thin package results in wasted months. Matching the question to the right rung on the ladder is a strategic decision in itself.

06 · WHY EARLY MATTERS

The case for engaging early

For a novel biologic, the most expensive mistakes are made before the first patient is dosed: the wrong animal model, a toxicology design that will not support the proposed clinical study, a manufacturing process that cannot demonstrate adequate product quality, or a first-in-human design that FDA will not accept. These decisions are costly to reverse and, if they surface only at IND review, can trigger a clinical hold that stops the program cold.

This is the gap INTERACT was built to close and give applicants a chance to get FDA’s read on a genuinely novel, challenging issue before you have committed to the definitive studies. The rest of this series picks up there: when to ask for an INTERACT meeting, what to put in front of FDA, and how to turn that early advice into a clean pre-IND and IND.

FDA sources & references

• OTP INTERACT Meetings — Office of Therapeutic Products guidance on INTERACT timing, package content, and denials. fda.gov ↗
• Formal Meetings Guidance — Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products (CDER/CBER). fda.gov ↗
• SOPP 8101.1 — Regulatory Meetings with Sponsors and Applicants for Drugs and Biological Products (CBER). fda.gov ↗
• Development & Approval (CBER) — IND and BLA processes for CBER-regulated products. fda.gov ↗
• Regulation — 21 CFR Part 312 (IND); 21 CFR Part 601 (BLA); PHS Act §351 (biologics) and §361 (low-risk tissue).

Planning a biologics program?

Deffai maps your development plan against FDA’s meeting ladder — so you ask for the right meeting, at the right time, with the right package.

Johnny Lam, PhD — Head of Regulatory Strategy · Laura Rose, PhD — Cofounder & Chief Regulatory Officer

This document is general educational information about FDA’s development and review process for biological products. It is not legal or regulatory advice and does not create an attorney–client or consulting relationship, nor does it substitute for FDA’s guidance documents, 21 CFR Parts 312 and 601, or SOPP 8101.1. Development pathways are highly product- and indication-specific. FDA meeting outcomes and advice are non-binding and based on the information presented. Confirm current FDA procedures and consider professional review of your specific program before acting.